EOLS Evolus Inc
Price (delayed)
$16.63
Market cap
$1.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$1.08B
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only
Highlights
EOLS's gross profit is up by 44% year-on-year and by 9% since the previous quarter
Evolus's revenue has increased by 41% YoY and by 8% QoQ
The quick ratio has grown by 48% year-on-year but it has declined by 10% since the previous quarter
The debt rose by 31% year-on-year
Key stats
What are the main financial stats of EOLS
Market
Valuations
Earnings
Shares outstanding
63.09M
Market cap
$1.05B
Enterprise value
$1.08B
Price to earnings (P/E)
N/A
Price to book (P/B)
53.91
Price to sales (P/S)
4.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.56
Revenue
$237.26M
EBIT
-$35.73M
EBITDA
-$29.6M
Free cash flow
-$20.15M
Per share
Balance sheet
Liquidity
EPS
-$0.9
Free cash flow per share
-$0.32
Book value per share
$0.31
Revenue per share
$3.78
TBVPS
$2.65
Total assets
$233.77M
Total liabilities
$214.46M
Debt
$126.75M
Equity
$19.31M
Working capital
$104.02M
Debt to equity
6.56
Current ratio
2.92
Quick ratio
2.53
Net debt/EBITDA
-1.12
Margins
Efficiency
Dividend
EBITDA margin
-12.5%
Gross margin
69.7%
Net margin
-22.4%
Operating margin
-16.3%
Return on assets
-26.1%
Return on equity
N/A
Return on invested capital
-26.6%
Return on capital employed
-19.9%
Return on sales
-15.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EOLS stock price
How has the Evolus stock price performed over time
Intraday
-4.92%
1 week
10.21%
1 month
15.89%
1 year
76.17%
YTD
57.93%
QTD
53.27%
Financial performance
How have Evolus's revenue and profit performed over time
Revenue
$237.26M
Gross profit
$165.42M
Operating income
-$38.7M
Net income
-$53.21M
Gross margin
69.7%
Net margin
-22.4%
The company's operating margin has surged by 51% YoY and by 22% QoQ
EOLS's gross profit is up by 44% year-on-year and by 9% since the previous quarter
The net margin rose by 43% year-on-year and by 18% since the previous quarter
Evolus's revenue has increased by 41% YoY and by 8% QoQ
Growth
What is Evolus's growth rate over time
Valuation
What is Evolus stock price valuation
P/E
N/A
P/B
53.91
P/S
4.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.56
The company's EPS rose by 24% YoY and by 13% QoQ
Evolus's equity has increased by 4.7% QoQ
The P/S is 49% more than the last 4 quarters average of 3.1 but 14% less than the 5-year quarterly average of 5.4
Evolus's revenue has increased by 41% YoY and by 8% QoQ
Efficiency
How efficient is Evolus business performance
The ROIC has soared by 56% YoY and by 24% from the previous quarter
The company's return on sales has surged by 54% YoY and by 25% QoQ
Evolus's ROA has increased by 31% YoY and by 18% from the previous quarter
Dividends
What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EOLS.
Financial health
How did Evolus financials performed over time
The total assets is 9% more than the total liabilities
The quick ratio has grown by 48% year-on-year but it has declined by 10% since the previous quarter
The total assets has increased by 38% YoY and by 3.4% from the previous quarter
Evolus's debt to equity has surged by 147% YoY but it has decreased by 4.5% QoQ
The debt rose by 31% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.